Lantern Pharma Stock (NASDAQ:LTRN), Quotes and News Summary
Lantern Pharma Stock (NASDAQ: LTRN) stock price, news, charts, stock research, profile.
Source: benzinga.com
📰 Lantern Pharma News
Page 4 - Lantern Pharma News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Lantern Pharma. Real-time updates on events, politics, business and more.
Lantern Pharma to Present Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-284 in Non-Hodgkin's Lymphomas at the Society of Hematologic Oncology Annual Meeting
Lantern Pharma Inc. , an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary AI and machine learning platform, RADR®, with multiple...
United States Jianli Zhou Society Of Hematologic Oncology Securities Exchange Exchange Commission On Starlight Therapeutics Inc
Source: marketscreener.com
We Think Lantern Pharma (NASDAQ:LTRN) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
How Is Lantern Pharma Cash Burn Changing Over Lantern Pharma Should We Worry About Lantern Pharma Free Cash Flow Cash Reserves
Source: yahoo.com
Meet the 500: Dr. Hubert Zajicek
The Health Wildcatters co-founder on the moment that changes his life, his organization's best exits, and more.
Southern Methodist University United States Upper Austria Hubert Zajieck University Of Vienna Health Wildcatters
Source: dmagazine.com
Lantern Pharma (LTRN) Set to Announce Quarterly Earnings on Wednesday
Lantern Pharma (NASDAQ:LTRN – Get Free Report) will be posting its quarterly earnings results after the market closes on Wednesday, August 9th. Analysts expect Lantern Pharma to post earnings of ($0.40) per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link. Lantern […]
Renaissance Technologies Lantern Pharma Inc Lantern Pharma Company Profile Commonwealth Equity Services Lantern Pharma Get Free Report
Source: tickerreport.com
RedChip Launches 'Small Stocks, Big Money' Podcast
RedChip Launches Small Stocks, Big Money Podcast
United States Barrett Boone Redchip Companies Sharps Technology Nasdaq News Network Redchip Companies Inc
Source: pr-inside.com
RedChip Launches 'Small Stocks, Big Money' Podcast
02.08.2023 - New podcast series shines a spotlight on undervalued small-cap and microcap stocksORLANDO, FL / ACCESSWIRE / August 2, 2023 / RedChip Companies, a renowned international investor relations firm specializing in microcap and small-cap ...
United States Sharps Technology Nasdaq Redchip Companies Inc Redchip Companies Reviva Pharmaceuticals Nasdaq Big Money
Source: wallstreet-online.de
Oncotarget Publishes New Data by Lantern Pharma, an AI Company Developing Cancer Therapies, Further Supporting Clinical Advancement of LP-284, a Novel Synthetically Lethal Drug Candidate for Non-Hodgkin's Lymphomas
Non-Hodgkin’s lymphoma (NHL) is the seventh leading cause of cancer in the US, with 20-40% of patients experiencing relapsed or refractory disease with limited or no therapeutic options. Publication highlights in vitro and in vivo results supporting LP-284’s development for mantle cell lymphoma (MCL), an aggressive form of B-cell non-Hodgkins lymphoma (NHL) with immediate patient needs. Lantern is anticipating filing the IND application with the FDA and initiating a first-in-human Ph...
Kishor Bhatia Securities Exchange Lantern Pharma Inc Starlight Therapeutics Inc Exchange Commission On Lantern Pharma
Source: marketscreener.com
Reuss Reviews the Development of LP-300 in Advanced NSCLC
Dr Reuss discusses the development of LP-300 in advanced NSCLC, the mechanisms of LP-300 that may help synergize with the activity of platinum-based chemotherapy, and its ongoing investigation in the phase 2 HARMONIC trial.
Source: onclive.com
Cancer Antibody Drug Conjugates Global Market to 2029: Look at more than 550 Drugs in Clinical Trial
/PRNewswire/ -- The "Global Cancer Antibody Drug Conjugates Market Size, Drug Sales, Drug Dosage, Price, & Clinical Trials Outlook 2029" report has been added...
Source: prnewswire.com